Back to top
more

Takeda Pharmaceutical Co. (TAK)

(Delayed Data from NYSE)

$13.17 USD

13.17
1,332,087

+0.14 (1.07%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $13.17 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for TAK

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Takeda Pharmaceutical Co falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Assets          
Cash & Equivalents -99,999 4,097 7,788 9,427 6,012
Receivables NA 5,045 6,447 7,640 7,221
Notes Receivable NA 0 0 0 0
Inventories NA 7,300 7,593 7,086 6,988
Other Current Assets NA 1,303 1,256 1,349 2,498
Total Current Assets NA 17,745 23,083 25,501 22,719
Net Property & Equipment NA 12,515 14,087 13,667 12,755
Investments & Advances NA 2,804 2,938 3,274 3,399
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 2,708 3,227 3,325 2,835
Intangibles NA 67,047 73,214 74,664 75,292
Deposits & Other Assets NA 469 735 943 955
Total Assets NA 103,287 117,284 121,376 117,954
Liabilities & Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Notes Payable NA 0 0 0 0
Accounts Payable NA 4,804 4,595 3,232 2,933
Current Portion Long-Term Debt NA 2,513 1,816 208 5,399
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 1,720 1,788 1,365 1,681
Other Current Liabilities NA 9,329 10,898 11,863 10,005
Total Current Liabilities NA 18,366 19,097 16,668 20,018
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 2,003 4,018 5,103 6,533
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 29,916 36,859 43,364 41,460
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 5,978 6,727 7,575 6,450
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 56,263 66,701 72,710 74,461
Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 12,405 14,919 15,681 15,347
Capital Surplus NA 12,793 15,209 15,871 15,459
Retained Earnings NA 11,404 13,169 14,193 12,604
Other Equity NA 11,164 8,319 3,480 888
Treasury Stock NA 742 1,032 560 805
Total Shareholder's Equity NA 47,025 50,583 48,665 43,493
Total Liabilities & Shareholder's Equity NA 103,287 117,284 121,376 117,954
Total Common Equity 0 47,025 50,583 48,665 43,493
Shares Outstanding 3,164.80 3,164.50 3,100.70 3,155.70 3,152.70
Book Value Per Share 0.00 14.86 16.31 15.42 13.80

Fiscal Year End for Takeda Pharmaceutical Co falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 2,158 2,303 2,691 4,097
Receivables NA 5,053 5,438 6,026 5,045
Notes Receivable NA 0 0 0 0
Inventories NA 7,954 7,975 7,909 7,300
Other Current Assets NA 1,351 1,272 1,420 1,303
Total Current Assets NA 16,516 16,988 18,046 17,745
Net Property & Equipment NA 12,522 13,070 13,106 12,515
Investments & Advances NA 2,536 2,873 2,873 2,804
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 2,153 2,320 2,741 2,708
Intangibles NA 62,617 66,954 70,782 67,047
Deposits & Other Assets NA 372 412 439 469
Total Assets NA 96,716 102,616 107,987 103,287
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 3,289 2,905 3,219 4,804
Current Portion Long-Term Debt NA 2,518 1,896 3,043 2,513
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 765 899 1,772 1,720
Other Current Liabilities NA 8,947 10,636 10,229 9,329
Total Current Liabilities NA 15,519 16,337 18,263 18,366
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 905 1,578 1,968 2,003
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 29,198 30,390 31,611 29,916
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 5,521 5,618 5,978
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 50,866 53,826 57,459 56,263
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 11,400 11,568 12,238 12,405
Capital Surplus NA 11,765 11,807 12,716 12,793
Retained Earnings NA 9,499 9,978 10,878 11,404
Other Equity NA 13,534 15,792 15,428 11,164
Treasury Stock NA 349 354 732 742
Total Shareholder's Equity NA 45,850 48,790 50,528 47,025
Total Liabilities & Shareholder's Equity NA 96,716 102,616 107,987 103,287
Total Common Equity 0 45,850 48,790 50,528 47,025
Shares Outstanding 3,164.80 3,164.70 3,164.70 3,164.60 3,164.50
Book Value Per Share 0.00 14.49 15.42 15.97 14.86